ArticleJournal of clinical medicine2021
Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- "Actionable" risk for preterm birth: patterns and prediction in California singleton births 2016-2020.BMC pregnancy and childbirth · 2026Article
- Integrating Clinical Factors and Parity-Specific Models with Molecular Biomarkers to Better Predict the Risk of Preterm Birth in Asymptomatic Women.Diagnostics (Basel, Switzerland) · 2026Article
- Plasma RNA-Based Dual Screening for Early/Extreme Spontaneous Preterm Birth and Early Onset Preeclampsia to Enable Prevention.Diagnostics (Basel, Switzerland) · 2026Article
- Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial.Pregnancy (Hoboken, N.J.) · 2026Article
- Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial.Diagnostics (Basel, Switzerland) · 2024Article
- Prediction and Prevention of Preterm Birth: Secondary Analysis of a Randomized Intervention Trial.Journal of clinical medicine · 2023Article
- A dual-binding magnetic immunoassay to predict spontaneous preterm birth.Frontiers in bioengineering and biotechnology · 2023Article
- Diagnostic or Therapeutic Strategies for Pregnancy Complications.Journal of clinical medicine · 2022Article
- Better Estimation of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating.Journal of clinical medicine · 2022Article
- Blood-based predictive biomarkers for preterm birth: Redefining risk stratification in modern perinatal care.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preterm births are the leading cause of neonatal death in the United States. Previously, a spontaneous preterm birth (sPTB) predictor based on the ratio of two proteins, IBP4/SHBG, was validated as a predictor of sPTB in the Proteomic Assessment of Preterm Risk (PAPR) study. In particular, a proteomic biomarker threshold of -1.37, corresponding to a ~two-fold increase or ~15% risk of sPTB, significantly stratified earlier deliveries. Guidelines for molecular tests advise replication in a second independent study. Here we tested whether the significant association between proteomic biomarker scores above the threshold and sPTB, and associated adverse outcomes, was replicated in a second independent study, the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP). The threshold significantly stratified subjects in PAPR and TREETOP for sPTB (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.